Compare BENF & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BENF | ANL |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.3M | 52.0M |
| IPO Year | N/A | 2023 |
| Metric | BENF | ANL |
|---|---|---|
| Price | $7.08 | $1.58 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 216.7K | 31.3K |
| Earning Date | 11-14-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $0.88 |
| 52 Week High | $12.48 | $2.99 |
| Indicator | BENF | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 89.64 | 49.96 |
| Support Level | $3.31 | $1.42 |
| Resistance Level | $7.21 | $1.70 |
| Average True Range (ATR) | 0.86 | 0.18 |
| MACD | 0.60 | 0.04 |
| Stochastic Oscillator | 90.58 | 65.39 |
Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.